12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sodium fusidate: Phase II started

Cempra began an open-label, U.S. Phase II trial in about 50 patients to compare oral CEM-102 plus rifampin for 6 weeks vs. standard of care consisting of IV antibiotics...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >